GET DAILY SIGNALSOnKure Therapeutics (OKUR) Analyst Targets Signal +497% Upside Potential
Key Takeaways
- The central stock price target of $15.50 is the arithmetic mean of four verified analyst price targets reviewed for OnKure Therapeutics, Inc. (OKUR), a clinical-stage biopharmaceutical company.
- The stock last closed near $2.60, so reaching $15.50 would require a rise of roughly 497% — a very large move by any standard.
- Individual analyst price targets range widely, from a low of $11 (Leerink Partners) to a high of $21 (H.C. Wainwright), reflecting major disagreement about the pipeline's value.
- The strongest supports are a cash-rich balance sheet, cash per share that exceeds the current share price, and a "Strong Buy"-leaning analyst view of the next-generation PI3Kα pipeline.
- The biggest risks are that the company is pre-revenue, is burning cash, has repeatedly seen price targets cut, and trades below its key moving averages.
Analyst Price Targets and Consensus View
OnKure Therapeutics is a clinical-stage precision-medicine company with no marketed products or revenue, so its valuation is driven almost entirely by analyst judgment about its drug pipeline rather than current financial results. Four verifiable analyst price targets were reviewed to build the central target: Leerink Partners set an Outperform rating with an $11 target (March 30, 2026), Oppenheimer's Matthew Biegler reiterated a Buy with a $14 target (August 14, 2026), LifeSci Capital's Sam Slutsky maintained a Buy with a $16 target (August 6, 2026), and H.C. Wainwright's Robert Burns reiterated a Buy with a $21 target (July 20, 2026). JonesTrading carries a Hold rating but does not publish a price target.
The mean of those four targets is $15.50, with a range of $11 to $21. That unusually wide spread signals genuine disagreement: the bulls are underwriting the next-generation PI3Kα programs, while more cautious analysts discount dilution and clinical-execution risk. Notably, every target has been cut from earlier, higher levels — Oppenheimer from $30, H.C. Wainwright from $27, and Leerink from $29 — as the company pivoted its strategy and raised capital. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
OKUR last traded around $2.60, giving the company a market capitalization near $105 million. Because the stock trades below its book value per share of roughly $4.25 and carries about $4.36 in cash per share, the shares are effectively pricing in substantial uncertainty about the pipeline. Reaching $15.50 would require a move of approximately 497% — a very large percentage advance for a pre-revenue biotech.
The theoretical path involves de-risking the company's next-generation PI3Kα pan-mutant selective inhibitors, OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for the first half of 2027. Any positive clinical data or a partnership could force a re-rating, but such outcomes are inherently uncertain and not guaranteed.
What Could Support a Move Toward the Target
The clearest support is financial: the company held roughly $176 million in cash at its most recent report, funded in part by a $150 million private placement led by Access Biotechnology. With cash per share above the current stock price and minimal debt, the balance sheet reduces near-term dilution overhang relative to many peers. The strategic pivot toward broader PI3Kα pan-mutant inhibitors has been framed by management as addressing a larger patient opportunity than the original OKI-219 H1047R-specific program. Four of the analysts publishing targets carry Buy or Outperform ratings, suggesting the sell-side broadly sees the risk-reward as skewed favorably despite the low share price.
What Could Prevent the Target From Being Reached
The principal obstacle is that OnKure generates no revenue and posted a trailing net loss near $59 million, so it depends on continued clinical and financing execution. The repeated downward revisions to price targets reflect concerns about share dilution, the shift in strategic focus, and the long timeline before potential commercialization. The stock also trades below its 50-day moving average (about $3.02) and its 200-day moving average (about $3.62), indicating weak technical momentum. A clinical setback, a regulatory delay, or further dilution could keep the shares well below even the lowest analyst target.
Technical Levels and Market Structure
The shares sit in the lower portion of a 52-week range of $2.01 to $5.38, near the lower bound. The $2.00 area has acted as a psychological and structural floor over the past year, while the 50-day and 200-day moving averages near $3.00 and $3.62 form overhead supply. A sustained recovery would need to clear those levels before the stock could begin a longer-term move toward analyst targets, which themselves sit far above any recent trading zone.
Time Horizon and What Investors Should Monitor
These analyst price targets generally reflect a roughly 12-month research horizon, though individual analysts do not publish identical timelines. Key upcoming items include quarterly earnings, guidance on cash runway, and updates on the OKI-345 and OKI-355 IND submissions expected in the first half of 2027. Investors should also watch for any clinical data readouts, partnering announcements, analyst target revisions, and changes in the company's financing plans, since any of these can materially shift sentiment for a pre-revenue biotech. From what I see, monitoring these milestones closely remains essential.
Using AI Daily Buy/Sell Signals for Monitoring
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like OKUR, such tools can help traders identify shifting trends and monitor positions more efficiently than manual chart review. In my view, this approach adds a useful layer when evaluating pre-revenue biotechs where sentiment can shift quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OKUR's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for OKUR turned positive on October 19, 2026. Looking at past instances where OKUR's MACD turned positive, the stock continued to rise in 15 of 16 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OKUR's RSI Oscillator exited the oversold zone, 8 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on OKUR as a result. In 24 of 29 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +12.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where OKUR advanced for three days, in 60 of 76 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
OKUR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OKUR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for OKUR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.611) is normal, around the industry mean (2.974). P/E Ratio (-0.856) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. OKUR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OKUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology